rs12980275 — IFNL3

Downstream variant near IFNL3 — third IL28B locus predictor of hepatitis C spontaneous clearance and treatment response; preferred tag for HCV pharmacogenomics in Asian populations where it was the original GWAS discovery signal

See your personal result for IFNL3

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IFNL3 rs12980275 — The Asian HCV Pharmacogenomics Marker

When Tanaka and colleagues performed a genome-wide association study in Japanese hepatitis C patients in 2009, two variants near the IL28B gene emerged with striking statistical force: rs8099917 and rs12980275. The latter — a simple A-to-G change on chromosome 19 — reached P=1.93×10⁻¹³ for null virological response and P=3.99×10⁻²⁴ for sustained virologic response, making it one of the most significant host genetic associations in hepatitis C pharmacogenomics. While rs12979860 later became the standard marker in European clinical practice, rs12980275 remains the preferred tag in Asian populations and HCV genotype-4 testing panels.

The variant sits approximately 1 kilobase downstream of the IFNL3 (formerly IL28B) gene on chromosome 19q13.13, in a regulatory region that influences expression of interferon lambda-311 interferon lambda-3
one of four type III interferons that restrict viral replication at mucosal and hepatic surfaces by activating the JAK-STAT pathway in epithelial cells and hepatocytes. The G allele at rs12980275 is in strong linkage disequilibrium22 linkage disequilibrium
non-random co-inheritance of nearby genetic variants with the T allele of rs12979860 (r²=0.68–1.0 depending on population) — meaning both tag the same underlying IFNL3/IFNL4 haplotype that impairs antiviral immunity.

The Mechanism

rs12980275 does not alter any protein sequence; its effect is regulatory. The G allele tags the same unfavourable haplotype across the IFNL3/IFNL4 region as rs12979860 T and rs8099917 G. On this haplotype, the functional causal variant is the ss469415590 frameshift (rs368234815)33 ss469415590 frameshift (rs368234815)
a dinucleotide variant in IFNL4 intron 1 that either creates or destroys functional interferon lambda-4 protein. The ΔG allele at rs368234815 — tagged by rs12980275 G — produces functional IFN-λ4 protein, which paradoxically impairs hepatitis C clearance by inducing endoplasmic reticulum stress in hepatocytes, pre-activating interferon-stimulated genes in ways that desensitise cells to exogenous interferon treatment, and dampening HCV-specific CD8+ T-cell responses.

The rs12980275 G allele also tags regulatory elements controlling IFNL3 transcription itself. In a haemodialysis cohort, the AG genotype was associated with elevated plasma IFN-λ3 levels, suggesting the variant influences IFNL3 expression in a complex dosage-dependent manner that differs between heterozygotes and GG homozygotes.

The Evidence

The Tanaka et al. 2009 GWAS44 Tanaka et al. 2009 GWAS in Japanese HCV genotype-1 patients was the discovery study for this marker. SVR rates declined sharply across genotypes: AA patients achieved approximately 76.9% SVR, while GG patients achieved only 12.5% — a striking gradient that established the clinical importance of this locus in Asian populations.

A meta-analysis of 16 studies comprising 2,786 patients55 meta-analysis of 16 studies comprising 2,786 patients found the AA genotype predicts significantly higher SVR than AG/GG genotypes with peginterferon/ribavirin. The overall odds ratio was approximately 2.88; in the Asian subgroup it was OR 3.08 (95% CI 1.45–6.54) and in Caucasians it was OR 2.74 (95% CI 1.53–4.92). The association held specifically for HCV genotypes 1 and 4.

In a Chinese Han cohort of 238 patients, rs12980275 AA was the only IL28B marker independently associated with rapid viral response66 rs12980275 AA was the only IL28B marker independently associated with rapid viral response. Carriers of AG/GG genotypes had an adjusted OR of 0.43 (95% CI 0.24–0.75) for achieving rapid viral response, confirming the G allele's predictive value specifically in this population.

Notably, in Korean patients where the AA genotype frequency reaches 87.2% and the GG genotype is essentially absent, IL28B testing including rs12980275 was found to have limited clinical utility precisely because the favourable genotype predominates. This mirrors the broader pattern across East Asia: the G allele frequency is only ~10% in East Asians compared to ~31% in Europeans and ~51% in Africans, making rs12980275 most clinically relevant in mixed or non-East-Asian populations.

Beyond hepatitis C, the G allele has been linked to impaired antiviral responses more broadly. In a Spanish surgical cohort, GG homozygotes had a 2.15-fold higher adjusted hazard of 28-day mortality during septic shock77 GG homozygotes had a 2.15-fold higher adjusted hazard of 28-day mortality during septic shock compared to AA carriers, consistent with impaired innate immune defence. In COVID-19 patients, the AA genotype was significantly enriched in survivors versus non-survivors88 the AA genotype was significantly enriched in survivors versus non-survivors, with GG genotype independently associated with severe disease in multivariate analysis.

Practical Actions

For hepatitis C management, rs12980275 provides essentially the same clinical information as rs12979860 in most populations. With modern pangenotypic direct-acting antivirals (DAAs), overall SVR rates exceed 95% regardless of IFNL3 genotype. The variant's main clinical relevance today lies in treatment duration decisions: GG carriers are not candidates for abbreviated 8-week protocols and should receive full 12-week courses. The variant also retains value for predicting the likelihood of spontaneous clearance in acute HCV infection.

For non-HCV health contexts, the G allele signal across septic shock and COVID-19 mortality suggests GG carriers have a broadly attenuated innate antiviral and antibacterial response, making vaccination and early treatment adherence particularly important.

Interactions

rs12980275 is in strong linkage disequilibrium with rs1297986099 linkage disequilibrium with rs12979860
r²=0.68–1.0 depending on population; both tag the same IFNL4/3 haplotype but with varying predictive weights across ancestries, and with rs80999171010 rs8099917
also in LD across the IFNL3/4 locus; the two were co-identified in the original Japanese GWAS, and with rs3682348151111 rs368234815
the true causal frameshift in IFNL4 that determines whether functional IFN-λ4 protein is produced. Commercial HCV pharmacogenomics panels often include rs12980275 alongside rs12979860 and rs8099917 because no single marker provides complete predictive information across all ancestries. The variants should not be treated as independent effects — they all tag the same underlying functional haplotype.

Drug Interactions

peginterferon alfa-2a reduced_efficacy literature
peginterferon alfa-2b reduced_efficacy literature
ribavirin reduced_efficacy literature
sofosbuvir reduced_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

AA Favourable IFNL3 Genotype Beneficial

Favourable antiviral genotype — best HCV clearance and interferon treatment response

You have two copies of the A allele at rs12980275, which tags the favourable IFNL3/IFNL4 haplotype. This is associated with the strongest innate antiviral immune response at hepatic surfaces, the highest rates of spontaneous hepatitis C clearance without treatment, and the best response to both interferon-based and direct-acting antiviral HCV therapy. About 48% of people of European descent carry this genotype; it is even more common in East Asian populations (~80%), where the favourable haplotype has reached near-fixation.

AG Intermediate IFNL3 Genotype Intermediate

Intermediate antiviral genotype — modestly reduced HCV clearance and treatment response

You carry one A allele and one G allele at rs12980275. This heterozygous genotype is associated with intermediate hepatitis C treatment outcomes — meaningfully better than GG but somewhat below AA. In the original Japanese GWAS, heterozygotes showed SVR rates between those of AA and GG carriers. Meta-analysis data confirm the AG genotype predicts lower odds of SVR than the AA genotype with peginterferon/ribavirin therapy. With modern direct-acting antivirals, overall cure rates remain high (above 90%), but this genotype is not suitable for abbreviated 8-week treatment protocols. About 43% of people of European descent carry this genotype.

GG Unfavourable IFNL3 Genotype Reduced

Unfavourable antiviral genotype — substantially impaired HCV clearance and treatment response

The GG genotype at rs12980275 tags the IFNL4-ΔG haplotype in which functional IFN-λ4 protein is produced. Chronic IFN-λ4 activity induces ER stress in hepatocytes, pre-activates interferon-stimulated genes in a way that reduces responsiveness to exogenous interferon treatment, and dampens HCV-specific CD8+ T-cell activation. The result is a cell environment that is poorly suited to clearing hepatitis C either spontaneously or during interferon-based therapy.

Beyond HCV, the impaired innate immune profile associated with this haplotype has been linked to higher mortality in septic shock (adjusted HR 2.15 versus AA carriers) and more severe COVID-19 outcomes — consistent with broadly attenuated antiviral and antibacterial defence at mucosal and hepatic surfaces.

Modern direct-acting antivirals circumvent the interferon pathway entirely, making them highly effective even for GG carriers. However, full 12-week treatment courses are necessary and early viral kinetics should be monitored closely.